Abstract: The present disclosure and invention relates to a chimeric protein useful in adoptive cell therapy (ACT) which is a membrane-associated signalling protein that can be induced to provide a cell expressing the protein with a STAT-5-mediated signal. Also provided are nucleic acid molecules encoding such a chimeric protein, 5 recombinant constructs, vectors and cells containing the nucleic acid molecule, methods of producing such cells, and therapeutic uses thereof.

Abstract: The invention relates to the use of a composition comprising adult human liver- derived progenitor cells, such as heterologous human adult liver-derived progenitor cells (HALPC), for the treatment of a patient having non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH), or wherein the patient is at risk of developing NASH. The treatment comprises a step of administering to said patient an amount of said composition which comprises a dose of 0.25 to 2.5 million said progenitor cells per kg body weight; wherein the composition is substantially free of an effective amount of an anticoagulant, and wherein the patient does not receive any co-treatment with an anticoagulant.

Abstract: The invention relates to the use of a composition comprising human adult liver-derived progenitor cells, such as heterologous human adult liver-derived progenitor cells (HALPC), for the treatment of a patient who has developed acute-on-chronic liver failure (ACLF) or is at risk of developing ACLF, wherein the treatment comprises a step of administering to said patient an amount of said composition which comprises a dose of 0.25 to 2.5 million said progenitor cells per kg body weight; wherein the composition is substantially free of an effective amount of an anticoagulant, and wherein the patient does not receive any co-treatment with an anticoagulant.

Abstract: The current invention concerns isolated liver progenitor cells, cell lines thereof, cell populations comprising such and compositions comprising such wherein the liver progenitor cells are HLA-E positive. In addition, the invention concerns methods of preparing these liver progenitor cells.

Abstract: Methods for treating an arthritic condition in a subject by administering to the subject at least one human Tr1 cell population directed to a joint-associated antigen.

Abstract: Compositions including human Treg cells directed to an eye-associated antigen and methods for treating uveitis.

Abstract: The present invention relates to methods for isolating Tr1 cells, resting Tr1 cells and/or activated Tr1 cells, to methods for enriching or depleting a cell population in Tr1 cells, resting Tr1 cells and/or activated Tr1 cells and to methods and kits for treating chronic inflammatory diseases, autoimmune diseases, allergic diseases, cancer and organ transplantation conditions.

Abstract: The present invention relates to compositions comprising human Tr1 cells directed to a joint-associated antigen and methods for treating an arthritic condition.

Abstract: The present invention relates to compositions comprising Tr1 cells and mesenchymal stem cells and methods for treating an autoimmune disease, an allergic disease or an inflammatory disease.